CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation von Loberg, Robert D., Day, LaShon L., Harwood, Jason, Ying, Chi, St. John, Lauren N., Giles, Ryan, Neeley, Chris K., Pienta, Kenneth J.

Volltext

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo von LOBERG, Robert D, YING, Chi, CRAIG, Matt, DAY, Lashon L, SARGENT, Erin, NEELEY, Chris, WOJNO, Kirk, SNYDER, Linda A, LI YAN, PIENTA, Kenneth J

Volltext

Inhibition of Decay-Accelerating Factor (CD55) Attenuates Prostate Cancer Growth and Survival In Vivo von Loberg, Robert D., Day, LaShon L., Dunn, Rodney, Kalikin, Linda M., Pienta, Kenneth J.

Volltext

Analysis of membrane-bound complement regulatory proteins in prostate cancer von Loberg, Robert D., Wojno, Kirk J., Day, LaShon L., Pienta, Kenneth J.

Volltext

Development of the VCaP androgen-independent model of prostate cancer von Loberg, Robert D., St. John, Lauren N., Day, LaShon L., Neeley, Chris K., Pienta, Kenneth J.

Volltext

PAR1-mediated NFκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism von Tantivejkul, Kwanchanit, Loberg, Robert D., Mawocha, Samkeliso C., Day, Lashon L., John, Lauren St, Pienta, Brian A., Rubin, Mark A., Pienta, Kenneth J.

Volltext

PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism von Tantivejkul, Kwanchanit, Loberg, Robert D, Mawocha, Samkeliso C, Day, Lashon L, John, Lauren St, Pienta, Brian A, Rubin, Mark A, Pienta, Kenneth J

Volltext